What is Polyplus?
Polyplus-transfection SA, established in 2001 and situated near the University of Strasbourg in France, is a key player in the biotechnology landscape. The company is dedicated to developing, marketing, and selling innovative solutions for the delivery of nucleic acids across in vivo, in vitro, and ex vivo applications. Its proprietary range of transfection reagents, which have been ISO 9001-certified since 2002, are integral to gene and oligonucleotide transfection and are increasingly utilized in global clinical trials. Polyplus holds a significant portfolio of patents and licenses in the critical field of nucleic acid delivery, positioning it as a leader in therapeutic development.
How much funding has Polyplus raised?
Polyplus has raised a total of $3.4M across 1 funding round:
Unspecified
$3.4M
Unspecified (2011): $3.4M, investors not publicly disclosed
What's next for Polyplus?
With a history of significant backing, including a substantial $3.4B investment in January 2011, Polyplus is well-positioned for continued expansion in the biopharmaceutical and research markets. The recent undisclosed funding round, coupled with its major enterprise-level capital infusion, suggests a strategic focus on scaling its operations and advancing its pipeline of nucleic acid delivery technologies. This financial backing is expected to accelerate the development and commercialization of its solutions, further solidifying its role in enabling cutting-edge therapeutics and research worldwide.
See full Polyplus company page
